Orna Therapeutics and Shanghai Simnova have announced an expansion of their strategic collaboration to develop RNA-based therapies in multiple myeloma.
The project, which will target the B-cell maturation antigen (BCMA), will combine Orna’s circular RNA technology with Simnova’s expertise in cell therapies.
Simnova will lead research, development, and commercialization of in vivo panCAR cell therapies targeting BCMA in China, while Orna retains rights for development and commercialization elsewhere.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze